PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Aridis Pharmaceuticals, Inc. (ARDS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS0403341045
CUSIP040334104
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$2.67M
EPS-$0.16
Revenue (TTM)$22.36M
Gross Profit (TTM)-$22.61M
EBITDA (TTM)-$347.00K
Year Range$0.05 - $0.54
Target Price$2.00
Short %6.80%
Short Ratio0.22

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Aridis Pharmaceuticals, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Aridis Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-30.00%-20.00%-10.00%0.00%10.00%20.00%30.00%NovemberDecember2024FebruaryMarchApril
-22.58%
22.58%
ARDS (Aridis Pharmaceuticals, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Aridis Pharmaceuticals, Inc. had a return of -10.13% year-to-date (YTD) and -70.00% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-10.13%6.33%
1 month-19.13%-2.81%
6 months-17.21%21.13%
1 year-70.00%24.56%
5 years (annualized)-64.08%11.55%
10 years (annualized)N/A10.55%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
20240.14%9.97%1.04%
2023-10.99%-7.64%-14.10%-13.46%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ARDS is 28, suggesting that the investment has average results relative to the market in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.

The Risk-Adjusted Performance Rank of ARDS is 2828
Aridis Pharmaceuticals, Inc.(ARDS)
The Sharpe Ratio Rank of ARDS is 2929Sharpe Ratio Rank
The Sortino Ratio Rank of ARDS is 3939Sortino Ratio Rank
The Omega Ratio Rank of ARDS is 3939Omega Ratio Rank
The Calmar Ratio Rank of ARDS is 1010Calmar Ratio Rank
The Martin Ratio Rank of ARDS is 2424Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Aridis Pharmaceuticals, Inc. (ARDS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ARDS
Sharpe ratio
The chart of Sharpe ratio for ARDS, currently valued at -0.40, compared to the broader market-2.00-1.000.001.002.003.00-0.40
Sortino ratio
The chart of Sortino ratio for ARDS, currently valued at 0.11, compared to the broader market-4.00-2.000.002.004.006.000.11
Omega ratio
The chart of Omega ratio for ARDS, currently valued at 1.01, compared to the broader market0.501.001.501.01
Calmar ratio
The chart of Calmar ratio for ARDS, currently valued at -0.73, compared to the broader market0.001.002.003.004.005.006.00-0.73
Martin ratio
The chart of Martin ratio for ARDS, currently valued at -1.05, compared to the broader market0.0010.0020.0030.00-1.05
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.91, compared to the broader market-2.00-1.000.001.002.003.001.91
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.77, compared to the broader market-4.00-2.000.002.004.006.002.77
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.46, compared to the broader market0.001.002.003.004.005.006.001.46
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.61, compared to the broader market0.0010.0020.0030.007.61

Sharpe Ratio

The current Aridis Pharmaceuticals, Inc. Sharpe ratio is -0.40. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.002.503.00NovemberDecember2024FebruaryMarchApril
-0.40
1.91
ARDS (Aridis Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Aridis Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-99.54%
-3.48%
ARDS (Aridis Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Aridis Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aridis Pharmaceuticals, Inc. was 99.58%, occurring on Oct 17, 2023. The portfolio has not yet recovered.

The current Aridis Pharmaceuticals, Inc. drawdown is 99.54%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.58%Sep 5, 20181274Oct 17, 2023
-1.47%Aug 31, 20181Aug 31, 20181Sep 4, 20182
-1.15%Aug 15, 20184Aug 20, 20183Aug 23, 20187

Volatility

Volatility Chart

The current Aridis Pharmaceuticals, Inc. volatility is 26.36%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%NovemberDecember2024FebruaryMarchApril
26.36%
3.59%
ARDS (Aridis Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Aridis Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items